Elixir Medical’s Dynamx Bioadaptor returns strong results

May 24, 2024 | 20:03

(0) user say

Elixir Medical, a developer of healthcare technology that treats cardiovascular and peripheral disease, has announced results from its two-year 'Bioadaptor Randomised Controlled Trial', comparing the DynamX Coronary Bioadaptor System to the industry standard Resolute OnyxTM Drug-Eluting Stent (DES).

Elixir Medical’s Dynamx Bioadaptor returns strong results

The results, following trials across 34 centres in Japan, Europe, and New Zealand, demonstrate a significant reduction in adverse events for the first time and the clinical advantage of the DynamX Bioadaptor. The data was presented at a late-breaking clinical session during the EuroPCR 2024 conference in Paris.

Shigeru Saito, director of the Division of Cardiology and Catheterisation Laboratory at Shonan Kamakura General Hospital in Japan, said, "These results from the two-year trial are very exciting–unlike anything we’ve ever seen before–and represent a new treatment category for patients living with coronary artery disease. The data shows that the Bioadaptor offers sustained, very low event rates across all major endpoints, making it a superior option compared to DES."

The DynamX bioadaptor is different from current standard-of-care therapies, as it is designed to return vessel health through different phases of adaption in the body to restore vessel biology and maintain consistent blood flow.

"We are beyond thrilled with the findings from the trial," said Motasim Sirhan, CEO of Elixir Medical. "Never before have we seen a vascular technology that addresses the limitations of existing therapies as we have with the DynamX Bioadaptor. These exceptional patient clinical outcomes further validate that the Bioadaptor is truly a transformative technology for the treatment of coronary artery disease."

Ha Noi hosts congress of cardiovascular-thoracic surgeons

More than 700 health experts from 22 countries are attending the 24th Congress of the Association of Thoracic and Cardiovascular Surgeons of Asia that opened in Ha Noi today.

Smartphone helps diagnose cardiovascular diseases via internet

With the assistance of smartphones, doctors can see the electrocardiography (ECG) process, which allows them to diagnose patients from afar.

Stakeholders seek to improve cardiovascular-renal-metabolic care in Vietnam

On May 15, more than 150 healthcare experts in both Hanoi and Ho Chi Minh City – including representatives from departments and agencies of the Ministry of Health, associations, doctors, and leading specialists in clinical research – gathered at a conference to discuss cardiovascular-renal-metabolic (CVRM) care.

By Vy Bui

What the stars mean:

★ Poor ★ ★ Promising ★★★ Good ★★★★ Very good ★★★★★ Exceptional